University of LiègeBCRU home page
Publications

 

See our publications


    Comblain F., Rocasalbas G., Gauthier S. and Henrotin Y. Chitosan: A promising polymer for cartilage repair and viscosupplementation. Biomed Mater Eng 2017;28 (s1): S209-S215. [Pubmed]

    Demoulin C., Depas Y., Vanderthommen M., Henrotin Y., Wolfs S., Cagnie B. and Hidalgo B. [Orthopaedic manual therapy : definition, characteristics and update on the situation in Belgium]. Rev Med Liege 2017;72 (3): 126-131. [Pubmed]

    Elayyan J., Lee E. J., Gabay O., Smith C. A., Qiq O., Reich E., Mobasheri A., Henrotin Y., Kimber S. J. and Dvir-Ginzberg M. LEF1-mediated MMP13 gene expression is repressed by SIRT1 in human chondrocytes. FASEB J 2017. [Pubmed]

    Luo Y., Sinkeviciute D., He Y., Karsdal M., Henrotin Y., Mobasheri A., Onnerfjord P. and Bay-Jensen A. The minor collagens in articular cartilage. Protein Cell 2017. [Pubmed]

    Sanchez C., Bay-Jensen A. C., Pap T., Dvir-Ginzberg M., Quasnichka H., Barrett-Jolley R., Mobasheri A. and Henrotin Y. Chondrocyte secretome: a source of novel insights and exploratory biomarkers of osteoarthritis. Osteoarthritis Cartilage 2017. [Pubmed]



    Bay-Jensen A. C., Henrotin Y., Karsdal M. and Mobasheri A. The Need for Predictive, Prognostic, Objective and Complementary Blood-Based Biomarkers in Osteoarthritis (OA). EBioMedicine 2016;7: 4-6. [Pubmed]

    Bay-Jensen A. C., Reker D., Kjelgaard-Petersen C. F., Mobasheri A., Karsdal M. A., Ladel C., Henrotin Y. and Thudium C. S. Osteoarthritis year in review 2015: soluble biomarkers and the BIPED criteria. Osteoarthritis Cartilage 2016;24 (1): 9-20. [Pubmed]

    Comblain F., Dubuc J. E., Lambert C., Sanchez C., Lesponne I., Serisier S. and Henrotin Y. Identification of Targets of a New Nutritional Mixture for Osteoarthritis Management Composed by Curcuminoids Extract, Hydrolyzed Collagen and Green Tea Extract. PLoS One 2016;11 (6): e0156902. [Pubmed]

    Comblain F., Serisier S., Barthelemy N., Balligand M. and Henrotin Y. Review of dietary supplements for the management of osteoarthritis in dogs in studies from 2004 to 2014. J Vet Pharmacol Ther 2016;39 (1): 1-15. [Pubmed]

    Demoulin C., Roussel N., Marty M., Mathy C., Genevay S., Henrotin Y., Tomasella M., Mahieu G. and Vanderthommen M. [the Maladaptive Beliefs of Patients with Low Back Pain. A Narrative Review]. Rev Med Liege 2016;71 (1): 40-6. [Pubmed]

    Henrotin Y., Sanchez C., Bay-Jensen A. C. and Mobasheri A. Osteoarthritis biomarkers derived from cartilage extracellular matrix: Current status and future perspectives. Ann Phys Rehabil Med 2016;59 (3): 145-8. [Pubmed]

    Hochberg M. C., Martel-Pelletier J., Monfort J., Moller I., Castillo J. R., Arden N., Berenbaum F., Blanco F. J., Conaghan P. G., Domenech G., Henrotin Y., Pap T., Richette P., Sawitzke A., du Souich P., Pelletier J. P. and Group M. I. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis 2016;75 (1): 37-44. [Pubmed]

    Moller I., Gharbi M., Martinez Serrano H., Herrero Barbero M., Verges Milano J. and Henrotin Y. Effect of chondroitin sulfate on soluble biomarkers of osteoarthritis: a method to analyze and interpret the results from an open-label trial in unilateral knee osteoarthritis patients. BMC Musculoskelet Disord 2016;17 (1): 416. [Pubmed]

    Runhaar J., Sanchez C., Taralla S., Henrotin Y. and Bierma-Zeinstra S. M. Fibulin-3 fragments are prognostic biomarkers of osteoarthritis incidence in overweight and obese women. Osteoarthritis Cartilage 2016;24 (4): 672-8. [Pubmed]

    Sahebkar A. and Henrotin Y. Analgesic Efficacy and Safety of Curcuminoids in Clinical Practice: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pain Med 2016;17 (6): 1192-202. [Pubmed]



    Comblain F., Sanchez C., Lesponne I., Balligand M., Serisier S. and Henrotin Y. Curcuminoids extract, hydrolyzed collagen and green tea extract synergically inhibit inflammatory and catabolic mediator's synthesis by normal bovine and osteoarthritic human chondrocytes in monolayer. PLoS One 2015;10 (3): e0121654. [Pubmed]

    Henrotin Y., Raman R., Richette P., Bard H., Jerosch J., Conrozier T., Chevalier X. and Migliore A. Consensus statement on viscosupplementation with hyaluronic acid for the management of osteoarthritis. Semin Arthritis Rheum 2015;45 (2): 140-9. [Pubmed]

    Horcajada M. N., Sanchez C., Membrez Scalfo F., Drion P., Comblain F., Taralla S., Donneau A. F., Offord E. A. and Henrotin Y. Oleuropein or rutin consumption decreases the spontaneous development of osteoarthritis in the Hartley guinea pig. Osteoarthritis Cartilage 2015;23 (1): 94-102. [Pubmed]

    Jordan J. M. and Henrotin Y. Osteoarthritis research society international initiative on recommendations for conducting clinical trials in osteoarthritis: overview. Osteoarthritis Cartilage 2015;23 (5): 671-3. [Pubmed]

    Kloppenburg M., Maheu E., Kraus V. B., Cicuttini F., Doherty M., Dreiser R. L., Henrotin Y., Jiang G. L., Mandl L., Martel-Pelletier J., Nelson A. E., Neogi T., Pelletier J. P., Punzi L., Ramonda R., Simon L. S., Wang S. and Group O. H. C. T. R. W. OARSI Clinical Trials Recommendations: Design and conduct of clinical trials for hand osteoarthritis. Osteoarthritis Cartilage 2015;23 (5): 772-86. [Pubmed]

    Kraus V. B., Blanco F. J., Englund M., Henrotin Y., Lohmander L. S., Losina E., Onnerfjord P. and Persiani S. OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis. Osteoarthritis Cartilage 2015;23 (5): 686-97. [Pubmed]

    Landsmeer M. L., Runhaar J., Henrotin Y. E., Middelkoop van M., Oei E. H., Vroegindeweij D., Reijman M., van Osch G. J., Koes B. W., Bindels P. J. and Bierma-Zeinstra S. M. Association of urinary biomarker COLL2-1NO2 with incident clinical and radiographic knee OA in overweight and obese women. Osteoarthritis Cartilage 2015;23 (8): 1398-404. [Pubmed]

    Lane N. E., Hochberg M. C., Nevitt M. C., Simon L. S., Nelson A. E., Doherty M., Henrotin Y. and Flechsenhar K. OARSI Clinical Trials Recommendations: Design and conduct of clinical trials for hip osteoarthritis. Osteoarthritis Cartilage 2015;23 (5): 761-71. [Pubmed]

    Mathy C., Cedraschi C., Broonen J. P., Azzi A. and Henrotin Y. Volition and low back pain: When patients talk. Ann Phys Rehabil Med 2015;58 (6): 326-31. [Pubmed]

    McAlindon T. E., Driban J. B., Henrotin Y., Hunter D. J., Jiang G. L., Skou S. T., Wang S. and Schnitzer T. OARSI Clinical Trials Recommendations: Design, conduct, and reporting of clinical trials for knee osteoarthritis. Osteoarthritis Cartilage 2015;23 (5): 747-60. [Pubmed]

    Oprenyeszk F., Sanchez C., Dubuc J. E., Maquet V., Henrist C., Compere P. and Henrotin Y. Chitosan enriched three-dimensional matrix reduces inflammatory and catabolic mediators production by human chondrocytes. PLoS One 2015;10 (5): e0128362. [Pubmed]

    Reeff J., Oprenyeszk F., Franck T., Goole J., De Vriese C., Serteyn D., Henrotin Y. and Amighi K. Development and evaluation in vitro and in vivo of injectable hydrolipidic gels with sustained-release properties for the management of articular pathologies such as osteoarthritis. Int J Pharm 2015;490 (1-2): 74-84. [Pubmed]

    Richette P., Chevalier X., Ea H. K., Eymard F., Henrotin Y., Ornetti P., Sellam J., Cucherat M. and Marty M. Hyaluronan for knee osteoarthritis: an updated meta-analysis of trials with low risk of bias. RMD Open 2015;1 (1): e000071. [Pubmed]

    Sanchez C., Horcajada M. N., Membrez Scalfo F., Ameye L., Offord E. and Henrotin Y. Carnosol Inhibits Pro-Inflammatory and Catabolic Mediators of Cartilage Breakdown in Human Osteoarthritic Chondrocytes and Mediates Cross-Talk between Subchondral Bone Osteoblasts and Chondrocytes. PLoS One 2015;10 (8): e0136118. [Pubmed]



    Henrotin Y. Does signaling pathway inhibition hold therapeutic promise for osteoarthritis? Joint Bone Spine 2014;81 (4): 281-3. [Pubmed]

    Henrotin Y., Gharbi M., Dierckxsens Y., Priem F., Marty M., Seidel L., Albert A., Heuse E., Bonnet V. and Castermans C. Decrease of a specific biomarker of collagen degradation in osteoarthritis, Coll2-1, by treatment with highly bioavailable curcumin during an exploratory clinical trial. BMC Complement Altern Med 2014;14: 159. [Pubmed]

    Henrotin Y., Lambert C. and Richette P. Importance of synovitis in osteoarthritis: evidence for the use of glycosaminoglycans against synovial inflammation. Semin Arthritis Rheum 2014;43 (5): 579-87. [Pubmed]

    Henrotin Y., Marty M. and Mobasheri A. What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis? Maturitas 2014;78 (3): 184-7. [Pubmed]

    Henrotin Y., Pesesse L. and Lambert C. Targeting the synovial angiogenesis as a novel treatment approach to osteoarthritis. Ther Adv Musculoskelet Dis 2014;6 (1): 20-34. [Pubmed]

    Lambert C., Dubuc J. E., Montell E., Verges J., Munaut C., Noel A. and Henrotin Y. Gene expression pattern of cells from inflamed and normal areas of osteoarthritis synovial membrane. Arthritis Rheumatol 2014;66 (4): 960-8. [Pubmed]

    McAlindon T. E., Bannuru R. R., Sullivan M. C., Arden N. K., Berenbaum F., Bierma-Zeinstra S. M., Hawker G. A., Henrotin Y., Hunter D. J., Kawaguchi H., Kwoh K., Lohmander S., Rannou F., Roos E. M. and Underwood M. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014;22 (3): 363-88. [Pubmed]

    McAlindon T. E., Bannuru R. R., Sullivan M. C., Arden N. K., Berenbaum F., Bierma-Zeinstra S. M., Hawker G. A., Henrotin Y., Hunter D. J., Kawaguchi H., Kwoh K., Lohmander S., Rannou F., Roos E. M. and Underwood M. Response to Letter to the Editor entitled "Comments on 'OARSI guidelines for the non-surgical management of knee osteoarthritis'". Osteoarthritis Cartilage 2014;22 (6): 890-1. [Pubmed]

    Pesesse L., Sanchez C., Walsh D. A., Delcour J. P., Baudouin C., Msika P. and Henrotin Y. Bone sialoprotein as a potential key factor implicated in the pathophysiology of osteoarthritis. Osteoarthritis Cartilage 2014;22 (4): 547-56. [Pubmed]



    Cedraschi C., Delezay S., Marty M., Berenbaum F., Bouhassira D., Henrotin Y., Laroche F. and Perrot S. "Let's talk about OA pain": a qualitative analysis of the perceptions of people suffering from OA. Towards the development of a specific pain OA-Related questionnaire, the Osteoarthritis Symptom Inventory Scale (OASIS). PLoS One 2013;8 (11): e79988. [Pubmed]

    Dobson F., Bennell K., Hinman R., Roos E., Abbott H., Stratford P., Davis A., Buchbinder R., Snyder-Mackler L., Hansen P., Thumboo J. and Henrotin Y. OARSI recommended performance-based tests to assess physical function in osteoarthritis of the hip or knee: authors' reply. Osteoarthritis Cartilage 2013;21 (10): 1625-6. [Pubmed]

    Dobson F., Hinman R. S., Roos E. M., Abbott J. H., Stratford P., Davis A. M., Buchbinder R., Snyder-Mackler L., Henrotin Y., Thumboo J., Hansen P. and Bennell K. L. OARSI recommended performance-based tests to assess physical function in people diagnosed with hip or knee osteoarthritis. Osteoarthritis Cartilage 2013;21 (8): 1042-52. [Pubmed]

    Gharbi M., Sanchez C., Mazzucchelli G., De Pauw E. and Henrotin Y. Identification of differential pattern of protein expression in canine osteoarthritis serum after anterior cruciate ligament transection: a proteomic analysis. Vet J 2013;197 (3): 848-53. [Pubmed]

    Henrotin Y., Chevalier X., Deberg M., Balblanc J. C., Richette P., Mulleman D., Maillet B., Rannou F., Piroth C., Mathieu P., Conrozier T. and Osteoarthritis Group of French Society of R. Early decrease of serum biomarkers of type II collagen degradation (Coll2-1) and joint inflammation (Coll2-1 NO(2) ) by hyaluronic acid intra-articular injections in patients with knee osteoarthritis: a research study part of the Biovisco study. J Orthop Res 2013;31 (6): 901-7. [Pubmed]

    Henrotin Y., Chevalier X., Herrero-Beaumont G., McAlindon T., Mobasheri A., Pavelka K., Schon C., Weinans H., Biesalski H. and Participants at the Hohenheim Consensus Conference in August t. Physiological effects of oral glucosamine on joint health: current status and consensus on future research priorities. BMC Res Notes 2013;6: 115. [Pubmed]

    Henrotin Y., Labasse A., Franck T., Bosseloir A., Bury T. and Deberg M. Collagen catabolism through Coll2-1 and Coll2-1NO2 and myeloperoxidase activity in marathon runners. Springerplus 2013;2 (1): 92. [Pubmed]

    Henrotin Y. and Lambert C. Chondroitin and glucosamine in the management of osteoarthritis: an update. Curr Rheumatol Rep 2013;15 (10): 361. [Pubmed]

    Henrotin Y., Priem F. and Mobasheri A. Curcumin: a new paradigm and therapeutic opportunity for the treatment of osteoarthritis: curcumin for osteoarthritis management. Springerplus 2013;2 (1): 56. [Pubmed]

    Hochberg M., Chevalier X., Henrotin Y., Hunter D. J. and Uebelhart D. Symptom and structure modification in osteoarthritis with pharmaceutical-grade chondroitin sulfate: what's the evidence? Curr Med Res Opin 2013;29 (3): 259-67. [Pubmed]

    Lambert C., Dubuc J. E., Montell E., Verges J., Munaut C., Noel A. and Henrotin Y. Gene expression pattern of synovial cells from inflammatory and normal areas of osteoarthritis synovial membrane. Arthritis Rheum 2013. [Pubmed]

    Oprenyeszk F., Chausson M., Maquet V., Dubuc J. E. and Henrotin Y. Protective effect of a new biomaterial against the development of experimental osteoarthritis lesions in rabbit: a pilot study evaluating the intra-articular injection of alginate-chitosan beads dispersed in an hydrogel. Osteoarthritis Cartilage 2013;21 (8): 1099-107. [Pubmed]

    Pesesse L., Sanchez C., Delcour J. P., Bellahcene A., Baudouin C., Msika P. and Henrotin Y. Consequences of chondrocyte hypertrophy on osteoarthritic cartilage: potential effect on angiogenesis. Osteoarthritis Cartilage 2013;21 (12): 1913-23. [Pubmed]



    Conrozier T., Balblanc J. C., Richette P., Mulleman D., Maillet B., Henrotin Y., Rannou F., Piroth C., Hilliquin P., Mathieu P., Walliser-Lohse A., Rousselot I., Plattner V., Maillefert J. F., Vignon E., Chevalier X. and Osteoarthritis Group of the French Society of R. Early effect of hyaluronic acid intra-articular injections on serum and urine biomarkers in patients with knee osteoarthritis: An open-label observational prospective study. J Orthop Res 2012;30 (5): 679-85. [Pubmed]

    Demoulin C., Marty M., Genevay S., Vanderthommen M., Mahieu G. and Henrotin Y. Effectiveness of preventive back educational interventions for low back pain: a critical review of randomized controlled clinical trials. Eur Spine J 2012;21 (12): 2520-30. [Pubmed]

    Henrotin Y. Osteoarthritis year 2011 in review: biochemical markers of osteoarthritis: an overview of research and initiatives. Osteoarthritis Cartilage 2012;20 (3): 215-7. [Pubmed]

    Henrotin Y., Gharbi M., Mazzucchelli G., Dubuc J. E., De Pauw E. and Deberg M. Fibulin 3 peptides Fib3-1 and Fib3-2 are potential biomarkers of osteoarthritis. Arthritis Rheum 2012;64 (7): 2260-7. [Pubmed]

    Henrotin Y., Hauzeur J. P., Bruel P. and Appelboom T. Intra-articular use of a medical device composed of hyaluronic acid and chondroitin sulfate (Structovial CS): effects on clinical, ultrasonographic and biological parameters. BMC Res Notes 2012;5: 407. [Pubmed]

    Henrotin Y., Martel-Pelletier J., Msika P., Guillou G. B. and Deberg M. Usefulness of specific OA biomarkers, Coll2-1 and Coll2-1NO2, in the anterior cruciate ligament OA canine model. Osteoarthritis Cartilage 2012;20 (7): 787-90. [Pubmed]

    Henrotin Y., Mobasheri A. and Marty M. Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis? Arthritis Res Ther 2012;14 (1): 201. [Pubmed]

    Henrotin Y., Pesesse L. and Sanchez C. Subchondral bone and osteoarthritis: biological and cellular aspects. Osteoporos Int 2012;23 Suppl 8: S847-51. [Pubmed]

    Henrotin Y. E. Interpretation of metaanalyses: pitfalls should be more widely recognized. J Rheumatol 2012;39 (6): 1107-9. [Pubmed]

    Lambert C., Mathy-Hartert M., Dubuc J. E., Montell E., Verges J., Munaut C., Noel A. and Henrotin Y. Characterization of synovial angiogenesis in osteoarthritis patients and its modulation by chondroitin sulfate. Arthritis Res Ther 2012;14 (2): R58. [Pubmed]

    Mobasheri A., Henrotin Y., Biesalski H. K. and Shakibaei M. Scientific evidence and rationale for the development of curcumin and resveratrol as nutraceutricals for joint health. Int J Mol Sci 2012;13 (4): 4202-32. [Pubmed]

    Punzi L., Ramonda R., Deberg M., Frallonardo P., Campana C., Musacchio E. and Henrotin Y. Coll2-1, Coll2-1NO2 and myeloperoxidase serum levels in erosive and non-erosive osteoarthritis of the hands. Osteoarthritis Cartilage 2012;20 (6): 557-61. [Pubmed]

    Sanchez C., Pesesse L., Gabay O., Delcour J. P., Msika P., Baudouin C. and Henrotin Y. E. Regulation of subchondral bone osteoblast metabolism by cyclic compression. Arthritis Rheum 2012;64 (4): 1193-203. [Pubmed]



    Gharbi M., Deberg M. and Henrotin Y. Application for proteomic techniques in studying osteoarthritis: a review. Front Physiol 2011;2: 90. [Pubmed]

    Henrotin Y. Muscle: a source of progenitor cells for bone fracture healing. BMC Med 2011;9: 136. [Pubmed]

    Mathy C., Broonen J. P., Henrotin Y., Marty M., Legout V., Genevay S., Duplan B., Bazin T., Laroche F., Savarieau B. and Cedraschi C. Development and validation of a questionnaire assessing volitional competencies to enhance the performance of physical activities in chronic low back pain patients. BMC Musculoskelet Disord 2011;12: 111. [Pubmed]

    Verwilghen D. R., Enzerink E., Martens A., Franck T., Balligand M., Henrotin Y., Detilleux J. and Serteyn D. Relationship between arthroscopic joint evaluation and the levels of Coll2-1, Coll2-1NO(2), and myeloperoxidase in the blood and synovial fluid of horses affected with osteochondrosis of the tarsocrural joint. Osteoarthritis Cartilage 2011;19 (11): 1323-9. [Pubmed]

    Verwilghen D. R., Martens A., Busschers E., Franck T., Deberg M., Henrotin Y., Vanderheyden L. and Serteyn D. Coll2-1, Coll2-1NO2 and myeloperoxidase concentrations in the synovial fluid of equine tarsocrural joints affected with osteochondrosis. Vet Res Commun 2011;35 (7): 401-8. [Pubmed]

    Henrotin Y., Lambert C., Couchourel D., Ripoll C. and Chiotelli E. Nutraceuticals: do they represent a new era in the management of osteoarthritis? - a narrative review from the lessons taken with five products. Osteoarthritis Cartilage 2011;19 (1): 1-21. [Pubmed]

    Kraus V. B., Burnett B., Coindreau J., Cottrell S., Eyre D., Gendreau M., Gardiner J., Garnero P., Hardin J., Henrotin Y., Heinegard D., Ko A., Lohmander S., Matthews G., Menetski J., Moskowitz R., Persiani S., Poole R., Rousseau J. C. and Todman M. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage 2011. [Pubmed]

    Perrot S., Marty M., Legout V., Moyse D., Henrotin Y. and Rozenberg S. Ecological or Recalled Assessments in Chronic Musculoskeletal Pain? A Comparative Study of Prospective and Recalled Pain Assessments in Low Back Pain and Lower Limb Painful Osteoarthritis. Pain Med 2011. [Pubmed]

    Pesesse L., Sanchez C. and Henrotin Y. Osteochondral plate angiogenesis: A new treatment target in osteoarthritis. Joint Bone Spine 2011;78 (2): 144-9. [Pubmed]

    Rego-Perez I., Fernandez-Moreno M., Deberg M., Pertega S., Fernandez-Lopez C., Oreiro N., Henrotin Y. and Blanco F. J. Mitochondrial DNA haplogroups and serum levels of proteolytic enzymes in patients with osteoarthritis. Ann Rheum Dis 2011;70 (4): 646-52. [Pubmed]



    Gabay O., Sanchez C. and Taboas J. M. Update in cartilage bio-engineering. Joint Bone Spine 2010;77 (4): 283-6. [Pubmed]

    Henrotin Y. and Chevalier X. [Guidelines for the management of knee and hip osteoarthritis: For Whom? Why? To do what?]. Presse Med 2010. [Pubmed]

    Henrotin Y., Clutterbuck A. L., Allaway D., Lodwig E. M., Harris P., Mathy-Hartert M., Shakibaei M. and Mobasheri A. Biological actions of curcumin on articular chondrocytes. Osteoarthritis Cartilage 2010;18 (2): 141-9. [Pubmed]

    Huebner J. L., Williams J. M., Deberg M., Henrotin Y. and Kraus V. B. Collagen fibril disruption occurs early in primary guinea pig knee osteoarthritis. Osteoarthritis Cartilage 2010;18 (3): 397-405. [Pubmed]

    Mobasheri A. and Henrotin Y. Identification, validation and qualification of biomarkers for osteoarthritis in humans and companion animals: mission for the next decade. Vet J 2010;185 (2): 95-7. [Pubmed]

    Rego-Perez I., Fernandez-Moreno M., Deberg M., Pertega S., Fenandez-Lopez C., Oreiro N., Henrotin Y. and Blanco F. J. Mitochondrial DNA haplogroups modulate the serum levels of biomarkers in patients with osteoarthritis. Ann Rheum Dis 2010;69 (5): 910-7. [Pubmed]

    Richette P., Eymard C., Deberg M., Vidaud D., de Kerguenec C., Valla D., Vicaut E., Bardin T. and Henrotin Y. Increase in type II collagen turnover after iron depletion in patients with hereditary haemochromatosis. Rheumatology (Oxford) 2010;49 (4): 760-6. [Pubmed]



    Henrotin Y. Need for high-standard translation methodology for the dissemination of guidelines. Osteoarthritis Cartilage 2009;17 (12): 1536-8. [Pubmed]

    Henrotin Y., Pesesse L. and Sanchez C. Subchondral bone in osteoarthritis physiopathology: state-of-the art and perspectives. Biomed Mater Eng 2009;19 (4-5): 311-6. [Pubmed]

    Mathy-Hartert M., Jacquemond-Collet I., Priem F., Sanchez C., Lambert C. and Henrotin Y. Curcumin inhibits pro-inflammatory mediators and metalloproteinase-3 production by chondrocytes. Inflamm Res 2009;58 (12): 899-908. [Pubmed]

    Chevalier X. and Henrotin Y. OARSI recommendations on knee and hip osteoarthritis: use with discernment. Joint Bone Spine 2009;76 (5): 455-7. [Pubmed]

    Herfs M., Herman L., Hubert P., Minner F., Arafa M., Roncarati P., Henrotin Y., Boniver J. and Delvenne P. High expression of PGE2 enzymatic pathways in cervical (pre)neoplastic lesions and functional consequences for antigen-presenting cells. Cancer Immunol Immunother 2009;58 (4): 603-14. [Pubmed]

    Marty M., Rozenberg S., Legout V., Durand-Zaleski I., Moyse D., Henrotin Y. and Perrot S. Influence of time, activities, and memory on the assessment of chronic low back pain intensity. Spine 2009;34 (15): 1604-9. [Pubmed]

    Sanchez C., Gabay O., Salvat C., Henrotin Y. E. and Berenbaum F. Mechanical loading highly increases IL-6 production and decreases OPG expression by osteoblasts. Osteoarthritis Cartilage 2009;17 (4): 473-81. [Pubmed]

    Verwilghen D., Busoni V., Gangl M., Franck T., Lejeune J. P., Vanderheyden L., Detilleux J., Grulke S., Deberg M., Henrotin Y. and Serteyn D. Relationship between biochemical markers and radiographic scores in the evaluation of the osteoarticular status of Warmblood stallions. Res Vet Sci 2009;87 (2): 319-28. [Pubmed]



    Gabay O., Hall D. J., Berenbaum F., Henrotin Y. and Sanchez C. Osteoarthritis and obesity: Experimental models. Joint Bone Spine 2008;75 (6): 675-679. [Pubmed]

    Sanchez C., Gabay O., Henrotin Y. E. and Berenbaum F. Osteoblast: A cell under compression. Biomed Mater Eng 2008;18 (4-5): 221-4. [Pubmed]

    Henrotin Y. Avocado/soybean unsaponifiable (ASU) to treat osteoarthritis: a clarification. Osteoarthritis Cartilage 2008;16 (9): 1118-9; author reply 1120. [Pubmed]

    Mathy-Hartert M., Hogge L., Sanchez C., Deby-Dupont G., Crielaard J. M. and Henrotin Y. Interleukin-1beta and interleukin-6 disturb the antioxidant enzyme system in bovine chondrocytes: a possible explanation for oxidative stress generation. Osteoarthritis Cartilage 2008;16 (7): 756-63. [Pubmed]

    Deberg M., Dubuc J. E., Labasse A., Sanchez C., Quettier E., Bosseloir A., Crielaard J. M. and Henrotin Y. One-year follow-up of Coll2-1, Coll2-1NO2 and myeloperoxydase serum levels in osteoarthritis patients after hip or knee replacement. Ann Rheum Dis 2008;67 (2): 168-74. [Pubmed]

    Sanchez C., Deberg M. A., Bellahcene A., Castronovo V., Msika P., Delcour J. P., Crielaard J. M. and Henrotin Y. E. Phenotypic characterization of osteoblasts from the sclerotic zones of osteoarthritic subchondral bone. Arthritis Rheum 2008;58 (2): 442-455. [Pubmed]



    Ameye L. G., Deberg M., Oliveira M., Labasse A., Aeschlimann J. M. and Henrotin Y. The chemical biomarkers C2C, Coll2-1, and Coll2-1NO2 provide complementary information on type II collagen catabolism in healthy and osteoarthritic mice. Arthritis Rheum 2007;56 (10): 3336-46. [Pubmed]

    Gangl M., Serteyn D., Lejeune J. P., Schneider N., Grulke S., Peters F., Vila T., Deby-Dupont G., Deberg M. and Henrotin Y. A type II-collagen derived peptide and its nitrated form as new markers of inflammation and cartilage degradation in equine osteochondral lesions. Res Vet Sci 2007;82 (1): 68-75. [Pubmed]

    Henrotin Y., Addison S., Kraus V. and Deberg M. Type II collagen markers in osteoarthritis: what do they indicate? Curr Opin Rheumatol 2007;19 (5): 444-50. [Pubmed]

    Henrotin Y. and Kurz B. Antioxidant to treat osteoarthritis: dream or reality? Curr Drug Targets 2007;8 (2): 347-57. [Pubmed]

    Lamour V., Detry C., Sanchez C., Henrotin Y., Castronovo V. and Bellahcene A. RUNX2 and HDAC3 mediated-repression is relieved in differentiating human osteoblast cells to allow high BSP expression. J Biol Chem 2007;282 (50): 36240-9. [Pubmed]

    Lejeune J. P., Serteyn D., Gangl M., Schneider N., Deby-Dupont G., Deberg M. and Henrotin Y. Plasma concentrations of a type II collagen-derived peptide and its nitrated form in growing Ardenner sound horses and in horses suffering from juvenile digital degenerative osteoarthropathy. Vet Res Commun 2007;31 (5): 591-601. [Pubmed]

    Marty M. and Henrotin Y. L’information du patient lombalgique. Rhumatologie Pratique 2007;242 (1-3).



    Bazin T., Henrotin Y., Cedraschi C., Duquesnoy B. and Duplan B. Pourquoi et comment imformer le patient lombalgique? Réflexions rhumatologiques 2006;10 (3): 32-5.

    Burton A. K., Balague F., Cardon G., Eriksen H. R., Henrotin Y., Lahad A., Leclerc A., Muller G. and van der Beek A. J. Chapter 2. European guidelines for prevention in low back pain : November 2004. Eur Spine J 2006;15 Suppl 2: S136-68. [Pubmed]

    Henrotin Y. Chondroprotective/structure-modifying drugs : a neverending story. Reumatissimo 2006;58: 15-6.

    Henrotin Y. Nutraceuticals in the management of osteoarthritis. – facts and Senses. European Companion Animal Health 2006: 18-20.

    Henrotin Y. Nutraceuticals in the management of osteoarthritis: an overview. Vet Pharmacol Ther 2006;29 (Suppl 1): 201-3.

    Henrotin Y., Rozenberg S., Balague F., Leclerc A., Roux E. and Cedraschi C. Recommandations européennes (COST B13) en matière de prévention et de prise en charge de la lombalgie non spécifique. Rev Rhum 2006;73 (Suppl 2): S33-52.

    Henrotin Y. E., Cedraschi C., Duplan B., Bazin T. and Duquesnoy B. Information and low back pain management: a systematic review. Spine 2006;31 (11): E326-34. [Pubmed]

    Henrotin Y. E., Deberg M. A., Crielaard J. M., Piccardi N., Msika P. and Sanchez C. Avocado/soybean unsaponifiables prevent the inhibitory effect of osteoarthritic subchondral osteoblasts on aggrecan and type II collagen synthesis by chondrocytes. J Rheumatol 2006;33 (8): 1668-78. [Pubmed]

    Lejeune J. P., Schneider N., Henrotin Y. and Serteyn D. L’ostéo-arthropathie dégénérative du cheval : Pathogénie et moyens diagnostiques. Ann Med Vet 2006;150: 173-92.



    Burton A. K., Balague F., Cardon G., Eriksen H. R., Henrotin Y., Lahad A., Leclerc A., Muller G. and van der Beek A. J. How to prevent low back pain. Best Pract Res Clin Rheumatol 2005;19 (4): 541-55. [Pubmed]

    Burton A. K., Balague F., Cardon G., Eriksen H. R., Henrotin Y., Lahad A., Leclerc A., Muller G. and van der Beek A. J. on behalf of the COST B13 Working Group on Guidelines for Prevention in Low Back Pain. European guidelines for prevention in low back pain 2005.

    Deberg M., Labasse A., Christgau S., Cloos P., Bang Henriksen D., Chapelle J. P., Zegels B., Reginster J. Y. and Henrotin Y. New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2005;13 (3): 258-65. [Pubmed]

    Deberg M. A., Labasse A. H., Collette J., Seidel L., Reginster J. Y. and Henrotin Y. E. One-year increase of Coll 2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression. Osteoarthritis Cartilage 2005;13 (12): 1059-65. [Pubmed]

    Demoulin C., Fauconnier C., Vanderthommen M. and Henrotin Y. [Recommendations for a basic functional assessment of low back pain]. Rev Med Liege 2005;60 (7-8): 661-8. [Pubmed]

    Henrotin Y., Kurz B. and Aigner T. Oxygen and reactive oxygen species in cartilage degradation: friends or foes? Osteoarthritis Cartilage 2005;13 (8): 643-54. [Pubmed]

    Henrotin Y., Sanchez C. and Balligand M. Pharmaceutical and nutraceutical management of canine osteoarthritis: present and future perspectives. Vet J 2005;170 (1): 113-23. [Pubmed]

    Jupsin I., Collette J., Henrotin Y., Bruyere O., Sarlet N. and Reginster J. Y. Strontium ranelate (Fujisawa/Servier). Curr Opin Investig Drugs 2005;6 (4): 435-44. [Pubmed]

    Martin G., Andriamanalijaona R., Mathy-Hartert M., Henrotin Y. and Pujol J. P. Comparative effects of IL-1beta and hydrogen peroxide (H2O2) on catabolic and anabolic gene expression in juvenile bovine chondrocytes. Osteoarthritis Cartilage 2005;13 (10): 915-24. [Pubmed]

    Mathy-Hartert M., Burton S., Deby-Dupont G., Devel P., Reginster J. Y. and Henrotin Y. Influence of oxygen tension on nitric oxide and prostaglandin E2 synthesis by bovine chondrocytes. Osteoarthritis Cartilage 2005;13 (1): 74-9. [Pubmed]

    Muller G., Burton A. K., Balague F., Cardon G., Eriksen H. R., Henrotin Y., Lahad A., Leclerc A. and Vanderbeek A. J. Evidence of the efficacy of preventive means for low back pain. Physioscience 2005;1: 100-12.

    Reginster J. Y., Bruyere O., Fraikin G. and Henrotin Y. Current concepts in the therapeutic management of osteoarthritis with glucosamine. Bull Hosp Jt Dis 2005;63 (1-2): 31-6. [Pubmed]

    Sanchez C., Deberg M. A., Piccardi N., Msika P., Reginster J. Y. and Henrotin Y. E. Osteoblasts from the sclerotic subchondral bone downregulate aggrecan but upregulate metalloproteinases expression by chondrocytes. This effect is mimicked by interleukin-6, -1beta and oncostatin M pre-treated non-sclerotic osteoblasts. Osteoarthritis Cartilage 2005;13 (11): 979-87. [Pubmed]

    Sanchez C., Deberg M. A., Piccardi N., Msika P., Reginster J. Y. and Henrotin Y. E. Subchondral bone osteoblasts induce phenotypic changes in human osteoarthritic chondrocytes. Osteoarthritis Cartilage 2005;13 (11): 988-97. [Pubmed]


    Christgau S., Henrotin Y., Tanko L. B., Rovati L. C., Collette J., Bruyere O., Deroisy R. and Reginster J. Y. Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate. Clin Exp Rheumatol 2004;22 (1): 36-42. [Pubmed]

    Henrotin Y., Deberg M., Dubuc J. E., Quettier E., Christgau S. and Reginster J. Y. Type II collagen peptides for measuring cartilage degradation. Biorheology 2004;41 (3-4): 543-7. [Pubmed]

    Martin G., Andriamanalijaona R., Grassel S., Dreier R., Mathy-Hartert M., Bogdanowicz P., Boumediene K., Henrotin Y., Bruckner P. and Pujol J. P. Effect of hypoxia and reoxygenation on gene expression and response to interleukin-1 in cultured articular chondrocytes. Arthritis Rheum 2004;50 (11): 3549-60. [Pubmed]

    Mouithys-Mickalad A., Deby-Dupont G., Mathy-Hartert M., Habraken Y., Nys M., Henrotin Y., Lamy M. and Deby C. Effects of glucocorticoids on the respiratory burst of Chlamydia-primed THP-1 cells. Biochem Biophys Res Commun 2004;318 (4): 941-8. [Pubmed]

    Reginster J. Y., Sarkar S., Zegels B., Henrotin Y., Bruyere O., Agnusdei D. and Collette J. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 2004;34 (2): 344-51. [Pubmed]

    Sanchez C., Deberg M. A., Burton S., Devel P., Reginster J. Y. and Henrotin Y. E. Differential regulation of chondrocyte metabolism by oncostatin M and interleukin-6. Osteoarthritis Cartilage 2004;12 (10): 801-10. [Pubmed]



    Bruyere O., Collette J. H., Ethgen O., Rovati L. C., Giacovelli G., Henrotin Y. E., Seidel L. and Reginster J. Y. Biochemical markers of bone and cartilage remodeling in prediction of longterm progression of knee osteoarthritis. J Rheumatol 2003;30 (5): 1043-50. [Pubmed]

    Bruyere O., Dardenne C., Lejeune E., Zegels B., Pahaut A., Richy F., Seidel L., Ethgen O., Henrotin Y. and Reginster J. Y. Subchondral tibial bone mineral density predicts future joint space narrowing at the medial femoro-tibial compartment in patients with knee osteoarthritis. Bone 2003;32 (5): 541-5. [Pubmed]

    Bruyere O., Henrotin Y. E., Honore A., Rovati L. C., Seidel L., Dardenne C. and Reginster J. Y. Impact of the joint space width measurement method on the design of knee osteoarthritis studies. Aging Clin Exp Res 2003;15 (2): 136-41. [Pubmed]

    Bruyere O., Honore A., Ethgen O., Rovati L. C., Giacovelli G., Henrotin Y. E., Seidel L. and Reginster J. Y. Correlation between radiographic severity of knee osteoarthritis and future disease progression. Results from a 3-year prospective, placebo-controlled study evaluating the effect of glucosamine sulfate. Osteoarthritis Cartilage 2003;11 (1): 1-5. [Pubmed]

    Henrotin Y. E., Bruckner P. and Pujol J. P. The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthritis Cartilage 2003;11 (10): 747-55. [Pubmed]

    Henrotin Y. E., Sanchez C., Deberg M. A., Piccardi N., Guillou G. B., Msika P. and Reginster J. Y. Avocado/soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and proinflammatory mediator production by human osteoarthritic chondrocytes. J Rheumatol 2003;30 (8): 1825-34. [Pubmed]

    Mathy-Hartert M., Burton S., Deby-Dupont G. and Henrotin Y. Le Rôle des antioxydants dans la prise en charge des maladies articulaires. Dieta 2003;33: 22-5.

    Mathy-Hartert M., Martin G., Devel P., Deby-Dupont G., Pujol J. P., Reginster J. Y. and Henrotin Y. Reactive oxygen species downregulate the expression of pro-inflammatory genes by human chondrocytes. Inflamm Res 2003;52 (3): 111-8. [Pubmed]

    Mayer F., Schlimberger A., van Cingel R., Henrotin Y., Laube W. and Schmidtbleicher D. Training and testing in open versus closed kinetic chain. Isokinetics and Exercise Science 2003;11: 181-7.

    Reginster J. Y., Bruyere O. and Henrotin Y. New perspectives in the management of osteoarthritis. structure modification: facts or fantasy? J Rheumatol Suppl 2003;67: 14-20. [Pubmed]

    Reginster J. Y., Bruyere O., Lecart M. P. and Henrotin Y. Naturocetic (glucosamine and chondroitin sulfate) compounds as structure-modifying drugs in the treatment of osteoarthritis. Curr Opin Rheumatol 2003;15 (5): 651-5. [Pubmed]

    Reginster J. Y., Kvasz A., Bruyere O. and Henrotin Y. Is there any rationale for prescribing hormone replacement therapy (HRT) to prevent or to treat osteoarthritis? Osteoarthritis Cartilage 2003;11 (2): 87-91. [Pubmed]

    Richy F., Bruyere O., Ethgen O., Cucherat M., Henrotin Y. and Reginster J. Y. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003;163 (13): 1514-22. [Pubmed]

    Sanchez C., Mathy-Hartert M., Deberg M. A., Ficheux H., Reginster J. Y. and Henrotin Y. E. Effects of rhein on human articular chondrocytes in alginate beads. Biochem Pharmacol 2003;65 (3): 377-88. [Pubmed]



    Ayache N., Boumediene K., Mathy-Hartert M., Reginster J. Y., Henrotin Y. and Pujol J. P. Expression of TGF-betas and their receptors is differentially modulated by reactive oxygen species and nitric oxide in human articular chondrocytes. Osteoarthritis Cartilage 2002;10 (5): 344-52. [Pubmed]

    Bruyere O., Honore A., Rovati L. C., Giacovelli G., Henrotin Y. E., Seidel L. and Reginster J. Y. Radiologic features poorly predict clinical outcomes in knee osteoarthritis. Scand J Rheumatol 2002;31 (1): 13-6. [Pubmed]

    Henrotin Y. NSAIDS: not just COX-2 inhibitors? . Intern Clin Pract Series 2002;19: 5-17.

    Henrotin Y., Ralet B., Dubuc J. E., Croisier J. L. and Crielaard J. M. Isokinetic evaluation of hip muscles in patients with coxarthrosis. Isokinetics and Exercise Science 2002;10: 21-22.

    Henrotin Y., Sanchez C. and Reginster J. Y. The inhibition of matrix metalloproteinases to treat osteoarthritis: reality and new perspectives. Expert Opin Ther Patents 2002;12 (1): 29-43.

    Mathy-Hartert M., Deby-Dupont G. P., Reginster J. Y., Ayache N., Pujol J. P. and Henrotin Y. E. Regulation by reactive oxygen species of interleukin-1beta, nitric oxide and prostaglandin E(2) production by human chondrocytes. Osteoarthritis Cartilage 2002;10 (7): 547-55. [Pubmed]

    Sanchez C., Mateus M. M., Defresne M. P., Crielaard J. M., Reginster J. Y. and Henrotin Y. E. Metabolism of human articular chondrocytes cultured in alginate beads. Longterm effects of interleukin 1beta and nonsteroidal antiinflammatory drugs. J Rheumatol 2002;29 (4): 772-82. [Pubmed]



    Appelboom T., Schuermans J., Verbruggen G., Henrotin Y. and Reginster J. Y. Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study. Scand J Rheumatol 2001;30 (4): 242-7. [Pubmed]

    Bruyere O., Henrotin Y., Honore A., Rovati L. C., Seidel L. and Reginster J. Y. Tibial subchondral sclerosis and femoral osteophytes are linked to symptomatic and structural severity of knee osteoarthritis. Clin Rheum 2001;20 (5): 411-412.

    de Leval X., Delarge J., Devel P., Neven P., Michaux C., Masereel B., Pirotte B., David J. L., Henrotin Y. and Dogne J. M. Evaluation of classical NSAIDs and COX-2 selective inhibitors on purified ovine enzymes and human whole blood. Prostaglandins Leukot Essent Fatty Acids 2001;64 (4-5): 211-6. [Pubmed]

    Henrotin Y., de Leval X., Mathy-Hartet M., Mouithys-Mickalad A., Deby-Dupont G., Dogne J. M., Delarge J. and Reginster J. Y. In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. Inflamm Res 2001;50 (8): 391-9. [Pubmed]

    Henrotin Y., Deby-Dupont G. and Reginster J. Y. [Biochemical mediators of inflammation]. Rev Med Liege 2001;56 (6): 433-42. [Pubmed]

    Henrotin Y., Labasse A., Zheng S. X., Galais P., Tsouderos Y., Crielaard J. M. and Reginster J. Y. Strontium ranelate increases cartilage matrix formation. J Bone Miner Res 2001;16 (2): 299-308. [Pubmed]

    Henrotin Y., vanderthommen M., Fauconnier C., Grisart J., Masquelier E., Peretz A., Toussaint F., Lemaitre D., Angenot P., Mahieu G., Rossion P., Bailly D., Mathy J. L., Chif D., Dechef P. and Crielaard J. M. Définition, critères de qualité et évaluation d'un programme de type école du dos. Recommandations de la Société Belge des Ecoles du Dos. Rev Rhum 2001;68: 185-91.

    Reginster J. Y., Deroisy R., Rovati L. C., Lee R. L., Lejeune E., Bruyere O., Giacovelli G., Henrotin Y., Dacre J. E. and Gossett C. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001;357 (9252): 251-6. [Pubmed]

    Reginster J. Y. and Henrotin Y. [Pharmacy clinics. How I treat...arthritis. First part: pathophysiologic recurrence and symptomatic treatment]. Rev Med Liege 2001;56 (2): 63-7. [Pubmed]

    Reginster J. Y. and Henrotin Y. [Pharmacy clinics. How I treat...Osteoarthritis. 2nd part: new therapeutic perspectives]. Rev Med Liege 2001;56 (3): 135-9. [Pubmed]

    Reginster J. Y., Henrotin Y., Christiansen C., Gamwell-Henriksen E., Bruyere, Collette J. and Christgau S. Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I. Calcif Tissue Int 2001;69 (3): 130-7. [Pubmed]

    Reginster J. Y., Paul I. and Henrotin Y. [What is the role of aceclofenac in the therapeutic arsenal against chronic osteoarthritis pathologies?]. Rev Med Liege 2001;56 (7): 484-8. [Pubmed]



    de Leval X., Delarge J., Somers F., de Tullio P., Henrotin Y., Pirotte B. and Dogne J. M. Recent advances in inducible cyclooxygenase (COX-2) inhibition. Curr Med Chem 2000;7 (10): 1041-62. [Pubmed]

    De Leval X., Henrotin Y., Labasse A. and Reginster J. Y. Comparison of the effects of nimesulide and nimesulide-L-lysine on PGE2 production by COX-1 and COX-2 and on chondrocyte metabolism in vitro. Pharm Pharmacol Commun 2000;6: 1-6.

    Henrotin Y., Croisier J. L., Reginster J. Y. and Crielaard J. M. Bases scientifiques du traitement physique de la gonarthrose. Kine 2000 2000;11: 86-94.

    Henrotin Y. E., Zheng S. X., Labasse A. H., Deby G. P., Crielaard J. M. and Reginster J. Y. Modulation of human chondrocyte metabolism by recombinant human interferon. Osteoarthritis Cartilage 2000;8 (6): 474-82. [Pubmed]

    Mouithys-Mickalad A. M., Zheng S. X., Deby-Dupont G. P., Deby C. M., Lamy M. M., Reginster J. Y. and Henrotin Y. E. In vitro study of the antioxidant properties of non steroidal anti-inflammatory drugs by chemiluminescence and electron spin resonance (ESR). Free Radic Res 2000;33 (5): 607-21. [Pubmed]

    Reginster J. Y., Gillot V., Bruyere O. and Henrotin Y. Evidence of nutriceutical effectiveness in the treatment of osteoarthritis. Curr Rheumatol Rep 2000;2 (6): 472-7. [Pubmed]

    Zheng S. X., Mouithys-Mickalad A., Deby-Dupont G. P., Deby C. M., Maroulis A. P., Labasse A. H., Lamy M. L., Crielaard J. M., Reginster J. Y. and Henrotin Y. E. In vitro study of the antioxidant properties of nimesulide and 4-OH nimesulide: effects on HRP- and luminol-dependent chemiluminescence produced by human chondrocytes. Osteoarthritis Cartilage 2000;8 (6): 419-25. [Pubmed]



    de Leval X., Dogne J. M., Neven P., Labasse A., Delarge J., Reginster J. Y. and Henrotin Y. Effects of nimesulide and indometacin on COX-1 and COX-2: a comparative study. J Pharm Belg 1999;54 (3): 89-90. [Pubmed]

    Henrotin Y. and Reginster J. Y. Anabolic events in osteoarthritis. Osteoarthritis Cartilage 1999;7 (3): 310-2. [Pubmed]

    Henrotin Y. and Reginster J. Y. Nonsteroidal antiinflammatory drugs and cartilage protection : an in vitro approach. Osteoarthritis Cartilage 1999;7: 355-7.

    Henrotin Y. E., Labasse A. H., Simonis P. E., Zheng S. X., Deby G. P., Famaey J. P., Crielaard J. M. and Reginster J. Y. Effects of nimesulide and sodium diclofenac on interleukin-6, interleukin-8, proteoglycans and prostaglandin E2 production by human articular chondrocytes in vitro. Clin Exp Rheumatol 1999;17 (2): 151-60. [Pubmed]

    Reginster J. Y., Halkin V., Henrotin Y. and Gosset C. Treatment of osteoporosis: role of bone-forming agents. Osteoporos Int 1999;9 Suppl 2: S91-6. [Pubmed]

    Reginster J. Y., Henrotin Y. and Gosset C. Promising new agents in osteoporosis. Drugs R D 1999;1 (3): 195-201. [Pubmed]



    Henrotin Y., Rossion P., Beriot A., Clarenne A., Minder A., Demoulin A. P., Godinas F. and Lejeune A. L'école du dos: une attitude préventive efficace. Nursing Today 1998;20: 26-7.

    Henrotin Y. E., Labasse A. H., Jaspar J. M., De Groote D. D., Zheng S. X., Guillou G. B. and Reginster J. Y. Effects of three avocado/soybean unsaponifiable mixtures on metalloproteinases, cytokines and prostaglandin E2 production by human articular chondrocytes. Clin Rheumatol 1998;17 (1): 31-9. [Pubmed]

    Henrotin Y. E., Zheng S. X., Deby G. P., Labasse A. H., Crielaard J. M. and Reginster J. Y. Nitric oxide downregulates interleukin 1beta (IL-1beta) stimulated IL-6, IL-8, and prostaglandin E2 production by human chondrocytes. J Rheumatol 1998;25 (8): 1595-601. [Pubmed]



    Bassleer C. T., Franchimont P. P., Henrotin Y. E., Franchimont N. M., Geenen V. G. and Reginster J. Y. Effects of ipriflavone and its metabolites on human articular chondrocytes cultivated in clusters. Osteoarthritis Cartilage 1996;4 (1): 1-8. [Pubmed]

    Henrotin Y. E., De Groote D. D., Labasse A. H., Gaspar S. E., Zheng S. X., Geenen V. G. and Reginster J. Y. Effects of exogenous IL-1 beta, TNF alpha, IL-6, IL-8 and LIF on cytokine production by human articular chondrocytes. Osteoarthritis Cartilage 1996;4 (3): 163-73. [Pubmed]



    Henrotin Y., De Groote D. D., Labasse A., Deby C., Geenen V. G. and Reginster J. Y. Cytokines and cartilage degradation. Mediators of Inflammation 1995;4 (3): 229-230.



    Bassleer C., Henrotin Y. and Franchimont P. Effects of ximoprofen and acetylsalicylic acid on human articular chondrocytes in three-dimensional culture. Drug Invest 1993;5 (1): 11-18.

    Henrotin Y., Deby-Dupont G., Deby C., De Bruyn M., Lamy M. and Franchimont P. Production of active oxygen species by isolated human chondrocytes. Br J Rheumatol 1993;32 (7): 562-7. [Pubmed]



    Bassleer C., Henrotin Y. and Franchimont P. Chondroitin sulfat: in vitro-wirkung auf differenzierte in agglomeraten kultivierte menschliche chondrozyten. Littera Rheumatol 1992;14: 43-52.

    Bassleer C., Henrotin Y. and Franchimont P. Effects of sodium naproxen on differentiated human chondrocytes cultivated in clusters. Clin Rheumatol 1992;11 (1): 60-5. [Pubmed]

    Bassleer C., Henrotin Y. and Franchimont P. In-vitro evaluation of drugs proposed as chondroprotective agents. Int J Tissue React 1992;14 (5): 231-41. [Pubmed]

    Bassleer C. T., Henrotin Y. E., Reginster J. L. and Franchimont P. P. Effects of tiaprofenic acid and acetylsalicylic acid on human articular chondrocytes in 3-dimensional culture. J Rheumatol 1992;19 (9): 1433-8. [Pubmed]

    Henrotin Y., Bassleer C. and Franchimont P. In vitro effects of Etodolac and acetylsalicylic acid on human chondrocyte metabolism. Agents Actions 1992;36 (3-4): 317-23. [Pubmed]

    Henrotin Y., Deby-Dupont G., Deby C., Franchimont P. and Emerit I. Active oxygen species, articular inflammation and cartilage damage. EXS 1992;62: 308-22. [Pubmed]



    Bassleer C., Henrotin Y. and Franchimont P. In vitro assays of chondrocyte functions: the influence of drugs and hormones. Scand J Rheumatol Suppl 1990;81: 13-20. [Pubmed]

    Henrotin Y., Bassleer C., Collette J., Nusgens B. and Franchimont P. Radioimmunoassay for human type II collagen. J Immunoassay 1990;11 (4): 555-78. [Pubmed]



    Franchimont P., Bassleer C. and Henrotin Y. Effects of hormones and drugs on cartilage repair. J Rheumatol Suppl 1989;18: 5-9. [Pubmed]

    Franchimont P., Bassleer C., Henrotin Y., Gysen P. and Bassleer R. Effects of human and salmon calcitonin on human articular chondrocytes cultivated in clusters. J Clin Endocrinol Metab 1989;69 (2): 259-66. [Pubmed]

    Henrotin Y., Bassleer C., Reginster J. Y. and Franchimont P. Effects of etodolac on human chondrocytes cultivated in three dimensional culture. Clin Rheumatol 1989;8 Suppl 1: 36-42. [Pubmed]



    Bassleer C., Henrotin Y., Bassleer R. and Franchimont P. Differentiated chondrocytes cultivated in clusters. Cytotechnology 1988;3: 39-40.



Haut de la page